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Abstract
The Gram-positive bacterium S. pneumoniae (the pneumococcus) is a major pathogen
of man causing community -acquired diseases worldwide. The 23-valent
polysaccharide (PS) vaccine can protect most of adults and children older than five,
but it cannot protect children under age 2, immunodeficiency patients and the elderly.
The PS conjugate vaccine which is complementaiy to the 23-valent PS vaccine is
highly immunogenic and protects children under the age of 2 against invasive diseases, 
.but its efficacy is threatened by stiain replacement and serotype switching since it 
.only protect against the limited number of serotypes contained within the vaccine. 
Therefore, it is important to develop new vaccines that can cope with those 
disadvantages.
,Pneumococcal virulence proteins have been studied extensively for their possible
application in production of an alternative vaccine. A protein-based vaccine is
expected to be immunogenic in all age groups including infants and the elderly.
Pneumococcal surface adhesin A (PsaA), pneumococcal surface protein A (PspA),
pneumococcal surface protein C (PspC), pneumolsyin (PLY) are the current leading 
.candidates, among them PLY is a very promising candidate for developing new 
,vaccines.
A promising road to protection against S. pneumoniae would be production of 
fusion protein-based mucosal vaccine. A mucosal vaccine, which can break the 
transmission chain of infection by preventing nasopharyngeal colonization, should 
protect children under 2 and immunodeficiency patients. Prevention of
nasopharyngeal colonisation by pneumococci can prevent horizontal spread of the 
pathogen, thus improving herd immunity to protect non-vaccinated people.
Previous work in our group demonstrates that PLY can act as a good adjuvant in PLY 
fused antigens to induce both systemic and mucosal immunity. The results from this 
project show truncated PLY lost this adjuvant property in antigen fused with truncated 
PLY; however, the adjuvant property in antigen fused with truncated PLY was 
restored in the presence of free PLY. NMR Chemical shift perturbation experiment 
showed a tryptophan residue maybe involved in the interaction between PLY and 
water-soluble cholesterol.
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1.1. Streptococcus pneumoniae
The Gram-positive bacterium S. pneumoniae (the pneumococcus) is a major pathogen 
causing community -acquired disease worldwide. Sternberg and Pasteur were the first 
to identify S. pneumoniae simultaneously in 1881 (Mitchell and KeiT 2002). S. 
pneumoniae was named as pneumococcus (Austrian 1999). The peumococcus 
asymptomatically colonises in the upper respiratory tract of human tract, and mainly 
infects patient at exti'eme age and those with immunodeficiency. The pneumoccocus 
can cause both non-invasive diseases, such as acute otitis media and sinusitis, and 
invasive diseases, such pneumonia, meningitis and sepsis. Pneumococcus infection 
causes high morbidity and mortality in both developing and developed countries. 
Every year in the USA, the pneumoccocus is estimated to cause 3000 cases of 
meningitis, 50,000 cases of bacteraemia, 500,000 cases of pneumonia and 7,000,000 
cases of otitis media (Obaro 2000). Even with advanced antimicrobial treatments and 
medical facilities, 40,000 people still die of pneumoccocal infection in the USA per 
year (Obaro, S. and R. Adegbola 2002). In developing countiies, 1 million children 
younger than 5 years old die from pneumoccocal infection per year ( Obaro, S. and R. 
Adegbola 2002). In recent years, antibiotic resistance has become a worldwide 
problem and further exacerbated the conditions since it limits the choices of 
antimicrobial agents; further more, the antimicrobial agents have to be used in the 
early stages of infection for high-risk groups such as children, elderly and 
immunodeficiency patients. Therefore, prevention of pneumococcal diseases by 
vaccination has become of great interest. Until now, many research groups have 
focused on the development of vaccines for particular high-risk groups.
12
1.2. Pneumococcal vaccine
Sir Almrotli E. Wright using killed, whole organisms developed the first pioneering
vaccine in 1911 (Watson et al., 1999), but the application failed because it only
covered one or two serotypes. The first successful pneumococcal vaccine (reviewed
(Bogaert, Hermans et al. 2004)) was developed using pneumococcal capsular 
.polysaccharide (PS) after Felton and Bailey ( reviewed in Bogaert, Hermans et al. 
2004) first isolated pneumococcal capsular PS. Tire vaccine was later abandoned 
because of the application of antibiotic therapy that is more effective than the vaccine 
to treat pneumococcal infections at that time(Austiian 1981). Emergence of the 
multidrug-resistant pneumococcus worldwide finally lead production of a 14-valent
developed to a 23-valent PS vaccine in 1983. Merck Research Laboratories USA
induce a B cell response that is T-cell independent. Though the 23-valent PS vaccine
Due to these above disadvantages associated with PS vaccine, the selected PSs are
pneumococcal PS vaccine in 1977 (Bogaert, Hermans et al. 2004), which in turn was
developed a licensed 23-valent PS vaccine named Pneumovax 23, which use 23- 
selected CPS from the 90 known serotypes. The 23-valent PS vaccines can only
3
can protect most adults and children older than five against infection by serotype
included in the vaccine, it has a very limited effect on the morbidity and mortality in 
.some groups due to its poor immunogenicity in these groups, such as the elderly, 
children under age two and immunodeficiency patient(Butler, Shapiro et al. 1999). It
■>T.i
does not cover all pneumococcus serotypes and is not effective against acute otitis 
media (Wadwa and Feigin 1999).
I 
.conjugated with a protein canier including tetanus toxoid or diphtheria toxoid to form 
the polyssacchride (PS) conjugate vaccine with improved efficacy(Dagan, Eskola et al.
13
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1998). Although different number of PSs has been conjugated to carrier protein and
evaluated, only one 7-valent PS conjugate vaccine has been licensed (Bogaert et al.,
2004). Though the PSP conjugated vaccine is highly immunogenic and protective
against invasive diseases in young children, and induces long-term protection
compared to the PS vaccine, which only induce relatively short-tenn protection, it
does not show any improved protection in the elderly (Shinefield and Black 2000). It 
.is still serotype specific and does not include some serotypes highly prevalent in
Africa, Asia and Oceania (Wuorimaa and kayhty, 2000). The number of PSs
connected to proteins is limited, because antigen competition and carrier protein
epitope suppression, which can impair the antibody response to PSs (Dagan et al.,
.1998), the PS conjugate vaccine only covers certain vaccine serotypes. Further more,
,;4'
Strain placement and serotype switching can cause long-term vaccine failure. A study 
of the efficacy of 7-valent conjugate vaccine against recurrent otitis media showed a 
shift in serotype distribution (Veenhoven, Bogaert et al. 2003). Finally, the PS 
conjugated vaccines are too expensive for developing countries ((Veenhoven, Bogaert 
et al. 2003); Obaro SK et al., 1996). Therefore, it is important to develop new 
vaccines that can cope with these disadvantages.
ÎThe PS conjugate vaccines are able to reduce nasopharynx colonisation of vaccine 
serotypes of the pneumococcus (Dagan et al., 1997 and 2000; Mbelle et al., 1999). As 
colonisation on nasopharynx is the first step of pneumococcal infection and 
asymptomatic colonisation in the upper respiratory tract is high, especially in children, 
elicitation of local mucosal immunity to eliminate nasopharynx colonisatiorr of the 
pneumococcus is potentially a good way to protect against pneumococcus (Bogaert et 
al., 2004; Zhang and Finn, 2004). Prevention of nasopharynx colonisation by the
a
pneumococcus can prevent horizontal the spread of the organism, thus improving herd 
immunity (Obaro, 2000; Zhang and Finn, 2004; Dagan and Fraser 2000), which 
protects unvaccinated people against pneumococcal infection. Haemophilus 
influenzae type b conjugate vaccines can elicit good mucosal immunity against if. 
influenzae infection, which results in a dramatic reduce in the incidence of H.
15
influenzae type b related invasive diseases and nasopharyngeal carriage (Zhang and IIFinn 2004).
1.3. Pneumococcal proteins as candidates of vaccine development
Pneumococcal proteins have been studied extensively as potential vaccine candidates.
A protein-based vaccine is expected to immunogenic in all age groups including
Jiinfants and the elderly. Broad and serotype independent protection can be elicited if 
highly conserved protein or protein epitopes or a combination of several proteins are 
included in vaccine. It is relatively cheap and simple to produce protein vaccine by
recombinant DNA technology. The potential candidates include pneumococcal
surface adhesin A (PsaA), pneumococcal surface protein A (PspA), pneumolysin I !
(Ply), pneumococcal surface protein C (PspC or CbpA), autolysin, neuraminidase and 
putative proteinase maturation protein A (PpmA) (Bogaert et al., 2004 and 2004a;
Zhang and Finn, 2004). Antibody against PsaA, PspA, PspC and Ply has been
demonstrated in human serum and mucosal secretions (Rapola et al., 2000).
PsaA, a member of the family of metal binding lipoproteins, is part of an ABC S
transporter and important for virulence (Bogaert et al., 2004). Immunisation studies 
with PsaA have shown significant protection against colonization but less protection 
in against invasive disease (Briles, Ades et al. 2000); (Seo, Seong et al. 2002). It was
1
induce protection against most clinical strains ((Briles, Hollingshead et al. 2000)).
16
showed that oral vaccination of mice with PsaA encapsulated in microalginate
.micro spheres induced significant protection against colonisation, pneumonia and 
septicaemia from an oral vaccination (Seo et al., 2002). Recently, Holmlund and co­
workers showed the increase of level of IgG concentration to PsaA were detected in 
the 7 weeks old infant, and the IgG concentration to PsaA in pneumococcal caniage
infants is significant higher than that in non-pneumococcal caniage groups (Holmlund 
et ah, 2006). Mice intraperitoneally challenge with DNA vaccine plasmid expressing
the PsaA induce humoral and cellular immune response against the pneumococcus 
.(Miyaji, Ferreira et al. 2002).
I
PspA and PspC are the members of the choline-binding group of proteins, which 
connect to the cell surface by non-covalent interactions with cell wall 
phosphoiylcholine (Mitchell and Ken, 2002). Intranasal immunisation of mice with 
PspA is protective against nasopharyngeal colonisation, and prevents pneumococcal 
diseases (Wu et al., 1997). The immunisation studies with PspA showed significant 
protection against invasive disease but reduced efficacy against mucosal disease and 
nasopharyngeal caniage (Wu et al., 1997; Ogunniyi et al., 2000; (Arulanandam,
Lynch et al. 2001). Mice intraperitoneally immunised with DNA vaccine plasmid 
expressing the truncated PspA can protect against intraperitoneal challenge with the 
virulent pneumococcus (Miyaji, Dias et al. 2003). Antibody selected from people
.1,4
vaccinated with PspA induces significant protection against pneumococci producing 
heterologous PspA (Briles, Hollingshead et al. 2000). Although PspA is structurally 
variable, the protection elicited by two or three PspA variants should be enough to
There are three neuraminidases in penumococci, Nan A, NanB andNanC. All 
pneumococcal isolates to date produce neuraminidase, but not all three (Jedrzejas
Pneumococcal alpha-enolase, immunoglobulin A1 protease, streptococcal lipoprotein 
rotamase A, and PpmA were showed to elicit antibody in children under age 2
17
However, development of new vaccine from PspA has slowed down because it has 
recently been found that PspA has the similarity to short sequences of human cardiac
myosin throughout the molecule (Holmlund et ah, 2006).
■
L
TPspC is also named Choline binding protein A (CbpA) and is important for
colonization and antibody induced by PspC can interfere with colonization
(Balachandran, Brooks-Walter et al. 2002). PspC is variable among different stiains
and antibody elicited by PspC is cross-reactive with PspA (Brooks-Walter, Briles et al.
1999). Mice intraperitoneally immunized with PspC were significantly better A
.protected than mice immunized with Ply toxoid alone against intraperitoneal : :
challenge of virulent pneumococcus (Ogunniyi et al., 2001). PspA and PspC are Air'.YTparalogous, and have a very similar domain structure and have similarity in much of 
their sequences (Brooks-Walter, Briles et al. 1999).
2001). Previous immunization study in the mice intranasal challenged by recombinant =|
neuraminidase suggests that PLY is more valuable than the neuraminidase A as a i;Ivaccine candidate (Lock and Frasch, 1998). Recently Tong and colleagues recently a
A
showed immunization with NanA could protect chinchillas against nasopharyngeal
■1colonisation (Tong et al., 2005). Pre-immunization of mice with autolysin was shown 
to be effective against a virulent wild type pneumococcus (Berry et al., 1989). I
antibodies that were cross-reactive with various pneumococcal strains (Overweg, Kerr 
et al. 2000), and the serum IgG antibody titers against PpmA is high in children with 
nasopharyngeal carriage of pneumococci (Vainio, Fagerlund et al. 2005).
18
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(Adrian, Bogaert et al. 2004). These proteins have potential as candidates for protein- 1Ibased vaccines, especially PpmA, it can elicit species-specific opsonophagocytic
I
Immunization with combination of these proteins can induce enhanced protection than 
immunization with individual protein (Briles et al., 2000 and 2003; Ogunniyi et al., 
2000 and 2001). The intranasal vaccination of mixture of PsaA and PspA can prevent 
nasopharyngeal carriage of pneumococci (Briles, Ades et al. 2000). Mice vaccinated 
with PLY and PspA can improve the protection against pneumococci compared to 
active vaccination with Ply alone (Briles, Hollingshead et al. 2003).
PLY, one of the most important virulent factors oi S. pneumoniae, is a member of the L
thiol-activated toxins and produced by almost all clinical isolates of the 
pneumococcus; PLY is a soluble 53 kDa monomer. PLY also belongs to the 
cholesterol-dependent cytolysin (CDC) family. It binds to cholesterol-containing cell 
membrane, arrd lyses all cells containing cholesterol in their membrane, PLY forms 
oligomeric pores containing 30 to 50 PLY monomers, which are believed to lyse cells 
by osmotic force. PLY has different biological effects in different organs and tissues.
PLY is able to interfere with human immunity and inflammatory response(Mitchell T 
J 2006). Sublytic concentrations of PLY are able to trigger inflammation and activate A
|:'"A
the complement pathway. PLY can slow ciliary beats in the bronchus and cause 
apoptosis in neutrophils, macrophages and neuronal cells (Mitchell T J 2006).
19
The structure of PLY is highly conserved among its variants, there is not much 
different with the primary structure (Mitchell T J 2006). How PLY binds cells and 
forms oligomeric pores are still not clear. There are two possible ways for pore 
formation by the CDC family. Studies from streptolysin O suggests that 
oligomerisation starts to form the pore after monomers bind and insert to the 
membrane (Palmer et ah, 1998). In contrast, studies from perfringolysin O (PFO) 
suggest that before the entire oligomer inserts to form the final pore, a prepore forms 
after monomers bind to the membrane. (Hotze et al., 2001; Hotze et al.,2002).
'i■44I 
1
However, streptolysin O also could form a prepore (Heuck et al., 2003). More
recently work with PLY suggests PLY forms a prepore before insertion of oligomer
■ "takes place (Tiley S J et al., 2005). PFO which is one of virulence factors of
Clostridium perfringens has almost the same molecular mass as PLY. There are 48%
1
s
sequence identity and 67% sequence similarity between PLY and PFO. The structure
of PFO (Rossjohn et al., 1997) provides a model of the conformational transition into
the pore form of model for PLY. Current understanding of PLY molecular mechanism
is guided by a model built on the basis of the crystal structure of PFO (Rossjohn et ak,
1997). PLY contains four domains (Figure 1. LA); each of them plays a different role
in the pore-forming process. Domain 1 plays a scaffold role that the other domains
can reorganize during pore forming. Domain 4 is responsible for initially binding to
cholesterol containing cell membrane by inserting a Trptophan rich loop into the 
,upper layer of a lipid bilayer. As the more arrd more toxin molecules bind to the
membrane, these monomers start to assemble a pre-pore due to interaction of domain
,1 and 3 among the toxins. Domain 2 begins to bend and dissociate with domain 3, and 
two sets of three a-helices hr domain 3 begin to refold into two long (3 hairpins.
.
Finally, the |3 hairpins insert into the lipid bilayer and form pores. These proposals are
I
supported by the fact that the domain 4 o f PLY is essential for PLY binding to sheep 
blood cell, and PLY without domain 4 (domains 1-3) is unable to bind to sheep 
erythrocyte membrane (Baba et a l, 2001).
Figure 1.1. Pore formation by Pneumolysin (W alz, 2005)
(A) crystal structure o f the soluble perfringolysin monomer (Rossjohn et al., 1997), 
the loop in 4 is tryptophan rich. (B-D) the structural rearrangements accompanying 
the pore formation (Tilley et al. 2005), (B) monomer, (C) prepore, (D) membrane 
inserted pore.
Purified human antibody to PLY can protect mice against virulent pneumococcal 
strains (Musher et a l, 2001). Immunization o f mice with PLY elicits protection 
against challenge with the pneumococcus (Ogunniyi et al., 2000 and 2001). PLY has 
been used as carrier in PS conjugate vaccines (Kuo et al, 1995; Lee et a l, 2001), and 
immunization o f mice with PS PLY toxoid conjugate vaccine showed rapid clearance
20
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produced from pneumococcal proteins can provide a broader protective immunity 
than that produced from non-pneumococcal proteins (Simell et al., 2001). A new PS 
PLY toxoid conjugate vaccine has been produced and being evaluated in our group
21
of the penuniococcus in the blood and provided a cross-protection against challenge
Îwith heterologous serotypes of virulent pneumococci (Lee et al., 2001), which means
PS conjugate vaccine using the pneumococcal protein as the carrier can provide a 
broader protective immunity than that using the non-pneumococcal proteins. However, 
PLY is too toxic to be used as vaccine directly, its mutant, PLY toxoid, is suitable 
candidate for generating new vaccine. PLY toxoid, AA146PLY lacking total 
hemolytic activity, is available in our group, and it remains as immunogenic as PLY 
in mice immunisation study (Kirkham et al., 2006). The PSP conjugate vaccines may 
induce mucosal immunity in addition to systemic immunity. Pneumococcal virulence 
proteins can act as carriers in the PSP conjugate vaccine. PS conjugate vaccine
A,
(unpublished data). Importantly, the Ply is not only a conjugate carrier but also induce A
an additional protection for broad protection against pneumococcal infection, it may fA-
elicit immunity complementary to PSs.
1.4. The advantage of PLY as a vaccine candidate
PLY is an ideal candidate for developing new penumococcal vaccine. Firstly, PLY is I
produced by almost all clinical isolates and its primary structure varies little; secondly,
PLY elicits T cell dependent immune responses and induce circulatory IgG and 
secretary IgA antibodies (Simell et al., 2001); third, PLY toxoid is a very effective 
immunogenic carrier in PS conjugate vaccines; finally, even if the vaccine fr om PLY
A'I
toxoid can not prevent all serotypes, vaccine elicited immunity to PLY can possibly 
result the less severe disease.
Previous work in our group showed that intranasal challenging mice with very low 
amount of PLY fusion protein resulted fast production of a significant large amount of 
specific IgG antibody in mice serum to the carried protein, and high levels of specific
22
«
IgA to the carried protein present in both the mucosal surface of nasopharynx and 
pulmonary tracts of mice. This suggested PLY could act as a good adjuvant in PLY 
fused antigens to induce both systematic and mucosal immunity (unpublished result).
A protein-based mucosal vaccine becomes possible if the fusion protein that contain 
PLY and the other virulence proteins of S. pneumoniae remains highly and mucosally 
immunogenic.
A mucosal vaccine, which can break the transmission chain of infection by preventing 
nasopharyngeal colonization, should protect children under 2 and immunodeficiency
■I
y
patients. Prevention of nasophaiynx colonisation of pneumococci can prevent 
horizontal spread of pathogen, thus improving herd immunity. The mucosal vaccine 
also has several advantages since it is administered intranasally and orally, it would 
avoid pain, and accidents associated with needles and hansmission of infection, and 
save budget on medical equipment and skilled personnel (Zhang and Finn, 2004). A
mucosal vaccine may also elicit systematic immunity, i.e. oral polio vaccine, which 
would further strengthen the immune system for protection against pathogen. Studies 
have suggested that oral or intranasal vaccine retain the same effectiveness as 
systemic application (Wu et al., 1997; Seo et al., 2002).
Native PLY is highly haemolytic, so we plan to fuse the carrier protein to specific 
.domains of PLY. The aims of my project are (i) determine which regions of PLY are 
,required for generating immune response, as we need to reduce toxicity while 
maintaining immunogenicity, (ii) determine whether we can use this technology to 
develop mucosal response is to other more relevant antigen, (iii) determine the 
structure of PLY in order to help understanding the mechanism of pore forming and 
above adjuvant property of PLY. Î■if
I
I
:
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Reagent Concentration and Volume pi
Forwards primer (20G) lOpM, 3pi
Reverse primer (20H) lOpM, 3 pi
Template (pET33b- 2pl
eGFPPLY)
DNTPs lOmM, 3 pi
DNase free d FLO 78pl
10 X Thenno poly buffer lOpl
Taq Ipl
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2.1. Construction of pET33b-eGFPD4ePLY, pET33b-eGFPD4PLY 
and pET33b-eGFPD123PLY
2.1.1. Plasmids
Plasmid pET33b (Merck Biosciences, Nottingham, UK), containing a kanamycin
resistance gene, was used. pET33b-D4PLY, pET33b-D4ePLY, pET33b-123PLY and
.pET33b-eGFPPLY contains gene sequence of domain 4 of PLY (D4PLY), extended 
domain 4 of PLY (D4ePLY), domain 123 of PLY (D123PLY) and eGFPPLY 
respectively (Figure 2.1. gene sequence of extended domain 4 of PLY is 15 bp longer
than that of domain 4PLY). pET33b-eGFPPLY and pET33b-PLY separately were 
constructed by Mr Graeme J. M. Cowan. 50pl of plasmids were prepared separately 
from Libraiy Efficiency® DH5a'^“ chemically competent (DH5a) E,coli (Invihogen,
Paisley, UK) using QIAprep Spin Miniprep Kit (Qiagen, West Sussex, UK) following 
the manufacturer instructions, DNA quality and quantity was measured by agarose gel 
electrophoresis. The eGFP coding sequence was amplified from plasmid pET33b- 
eGFPPLY by Polymerase Chain Reaction (PCR, Table 2.1.1.) using Taq polymerase 
(Taq; Promega) and primers 20G and 20H (Table2.1.2. ).
fTable 2.1.1. The PCR for amplifying eGFP gene
!
A
Figure 2.1. A simple illustration of the differences between 
eGFPD4ePLY, eGFPD4PLY and eGFPDI23PLY
N-teniiiiinl C-teuiiiiial
PLY
His tag
Domain 123 of PLY Domain 4 of PL Y 
(D123PLY) (D4PLY)
His tag
eGFP-doinaiii 123 of PLY 
(eGFPD123PLY)
eGFP-domain 4 of PLY 
(eGFPD4PLY)
Els tag
l y ' y :
eGFP-extended domain 4 of PL Y 
(eGFPD4ePLY)
2.1.2. Enzyme digestion and ligation
The purified plasmids were then digested with 2pl each o f Nhe\ and BamHl (Figure 
2.1.1) restriction enzymes (Promega, Sounthampton, UK) in 6pl o f Muti-core^^buffer 
at 37®C for 2 hours. The cut plasmids were treated with Ipl o f ealf intestinal alkaline 
phosphatase (promega) at 37”C for 30mins and cleaned up using gel purification kit 
(Qiagen). The PCR products from pET33b-eGFPPLY were cleaned using gel 
purification kit (Qiagen), digested using 2pl each of restriction enzyme Nhel and 
Bg\\\ (Promega) at 37®C for 2 hours and purified again using gel purification kit. 1 pi 
of cleaned cut PCR products were ligated with 3pl o f cut plasmids using Ipl of T4 
DNA ligase in ip l o f ligation buffer phis 4pl o f Dnase free dHiO at room temperature 
for 4 hours.
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2.1.3, Transformation and DNA sequencing
Ligated plasmids were transformed into Library Efficiency® DH5a‘‘^  ^chemically 
competent E. coli following the instructions manufacturer provided (Invitrogen).
Bacteria were grown overnight on the Luria-Bertani broth ( LB broth; Sigma-Adrich,
Doreset, UK) agar plate containing 50pg/ml kanamycin at 37°C. PCR was performed 
in order to confirai the transformation using primers 7F and 7G (Table 2.1) flanking 
to the gene inserted. The PCR confirmed clones were grown in 10ml LB containing 
50|ug/ml kanamycin overnight at 37°C with shaking at 220rpm. Bacterial stock with 
10% glycerol was made and 1ml aliquots were then stored at -80”C. Plasmids were 
purified from culture (Qiagen) and then sent for DNA sequence. 30pl of all three 
plasmids were sent to the Molecular Biology Support Unit, University of Glasgow 
and to DBSGENOMICS at Durham University for sequencing using primers 33Z,
34A and 7F (Table 2.1.1). Data for DNA sequence were analysed by Vector NTY*^
Advance 10 software (Invitrogen). After the DNA sequences were proven to be 
correct, Plasmids including pET33b-eGFPD4PLY, pET33b-eGFPD4PLY, pET33b- 
eGFP123PLY, pET33b-123PLY and pET33b-D4ePLY were electi'o-transfoimed into 
BL21 E.coli (Shatagene) for expression by electroporation using BioRad Gene Puiser 
following the manufacturer inshuctions provided.
7
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Prim er Ref Prim er Name Sequence (5’ to 3’)
20G GFP pET33b Fwd GTC AGG CTA GCA TGA GTA AAG GAG 
AAG AAC
20H GFPpET33b Rev CCA CGC AGA TCT TTG TAT AGT TCA TCC
7F T7 old Fwd TAA TAG GAC TCA CTA TAG GG
7G T7 old Rev GCT AGT TAT TGC TCA GCG GTG
33Z eGFPseql TTGCACTACTGGAAAACTAC
34A eGFPseq2 CATGGCAGACAAACAAAAAGAA
kanamycin with shaking at 220rpm at 30°C. ImM Isopropyl-P-D-thio-
at 220rpm. Cell Pellets were resuspended in 4^C 50 ml 1 x phosphate buffered saline 
PBS (Oxoid, UK) with 5|ug of the proteinase inhibitor Benzamidine and DNAnase I 
(Sigma-Aldrich, Dorset, UK) per litre of cell pellets, Bacterial pellet suspension were 
sonicated 4 times for 30 seconds at 100% by cell sonicator (Constant systems Ltd, 
Warwick, UK), one minute break between each time. The lysates were centrifuged at 
18000g for 30 minutes at 4°C to remove cell debris. The supernatant were filtered by 
syringe using 0.22pm filter (Sartorius, Hannover, Germany).
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Table 2.1.2. Primers used for construction expression vector
I
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2.2. Proteins expression and purification
2.2.1 Protein expression
.The BL21 E.coli containing different plasmids separately were grown in 1 lihe of 
terrific broth (TB) or M9 Minimal medium (M9, Appendix I) containing 50pg/ml
galactopyranoside (IPTG) was added to induce expression of the recombinant proteins
when the OD^ oo of cell cultures was reached lin TB or the OD^o of cell cultures was 
reached 0.8 in M9; The bacterial cells were harvested by centrifugation at 4^C after 
they were grown for a further 6 hours in TB or 10 hours in M9 at 30°C with shaking
I
II
2.2.2 Protein purification
2,2.2.1. Nickel affinity chromatography (NAC)
Because expression vector pETT33b is designed to leave six histidines (His tag) at the
continuous gradient of imidazole in phosphate buffered saline (PBS)(Oxford). 25 
fractions with increased concentration of imidazole were collected. Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to select the right 
fraction which only contains one right size protein, the other fractions with 
contaminants were discarded.
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N-terminus of the proteins, proteins can be purified by immobilised metal affinity
chromatography since His tag can interact tightly with metal. The bacterial cell
supernatants were passed through a Nickel-charged NT A ( Nitrilotriacetic acid resin)
Superflow column (Qiagen) by fast protein liquid chromatography system (FPLCS).
The His tagged proteins stayed on the column, and the other proteins and bacterial
.component were eluted. The His-tagged proteins then were eluted with a 0-250mM
A
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2.2,2.2. Anion exchange chromatography (AEG)
Purified recombinant proteins were further purified by AEG using Poros ® HQ20 
Micron media on a BioCad 700E workstation (Applied Biosystems Ltd, Warrington,
UK) in order to exclude DNA and lipopolysacchrides (LPS). The recombinant 
proteins were eluted with O.IM NaCl while DNA, LPS and the other contaminants 
still bound to the column.
Î
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2.2.2,3. Dialysis
'S
Dialysis tubing with 8 KDa molecular weigh cut off (Medicell International Ltd,
London, UK) was boiled in lOmM sodium bicarbonate solution with ImM EDTA for 
10 mills, washed with sterile PBS and stored at 4°C with 20% ethanol. The proteins 
were dialysed three times against a greater than 50-fold volume of 1 x PBS at 4°C.
Amicon ultra centrifugal filters (Millipore, Watford, UK) were used to concentrate the 
proteins; Amicon ultra centrifugal filters were also used to cut off the small amount of
contaminating proteins during purification of eGFPD123PLY. All proteins were 
filtered by syringe using 0.22pm filter (Sartorius) before aliquoted and stored at -80°C.
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2.3 Analysis of purified proteins
2.3.1 Protein concentration
The amount of protein can be determined by measuring the absorbance by 
spectrophotometer at 280nm. Purified samples have a low A260 (DNA concentration) 
and a low A320 ( protein aggregates). The absorbance at 280nmm was divided by the 
extinction coefficient (E) of proteins. Protein concentration was also measured using a 
standard Bradford assay. A standard curve was prepared from 2mg/ml of Bovine 
serum albumin (BSA) to Omg/ml. 10 pi of standard and samples in duplicate were Itransferred into a flat bottom 96 well plate, 200pl of Bradford’s reagent was then A
fadded (Bio-rad, Hertfordshire, UK). Absorbance was measure at 570nm and the
'/Aprotein concentration was determined by the standard curve. I
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2,3,2. SDS-PAGE and Western Blotting
Proteins were analysed using 10% Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western blotting for presence of other 
contaminating proteins or degi adation of the proteins. 2-10pi of samples were mixed 
with 5 X loading buffer and boiled for 5 min at 95 C before loading on gels. Precision
2.3.3. Haemolytic assay
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Plus Protein standards Kaleidoscope‘s^  marker (Bio-Rad) was used for indicating
proteins’ size. All gels were run at 200 Volts for 40 min, then either stained or
■
transferred to Hybond-C nitrocellulose membrane (Amersham Biosciences,
Buckinghamshire, UK) and blotted at 100 Volts for 60 min. The membranes were 
blocked in 3% skimmed milk (in Tris-NaCl PH 7.4) overnight at 4°C with shaking.
Membranes were then incubated with first antibody (1:2000 dilution in 3% skimmed 
milk) for two hours at 37°C with shaking. Anti-PLY, anti-eGFP and anti-His-tag 
antibody were used in Western blotting as the first antibody. Membranes were then 
washed four times with Tris-Nacl (PH 7.4) buffer and incubated with HRP-Linked 
second antibody (1:2000 dilution in 3% skimmed milk; Amersham Biosciences ) for 
two hours at 37°C with shaking. Membranes were washed four times and finally 
developed with developer. For more details, please see Appendix I.
I
Round- and flat-bottomed 96-well plates (R-plate and F-plate; Nunc^'^, Danmark) 
were both used for haemolytic assay. 1ml of horse blood was centrifuged for 1 min at 
13k rpm in an eppendorf tube. The supernatant was removed and the pellet was 
resuspended in same volume of PBS. Above process was repeated 5 times in order to 
move lysed cell and antibodies completely. 2% horse blood was prepared by adding 
400pl washed horse blood to 20 ml PBS. lOOpl of PBS was added into required wells
row 3 from row 2. Above step was repeated until lOOpl was discarded from bottom
spectrophotometer (96 well plate reader) at 540nM.
2.3,4, Cell binding assay by fluorescence microscopy
Horse blood was prepared following the method in haemolytic assay. Lysed horse
:'ÿ:
of a R-plate by multi-channel pipette. lOOjal of PBS (negative control) and samples
were then added into the wells in row 1, and lOOpl of solution was transfenud into
,row 2 from row 1. The tips were changed and 100pi of solution was transferred into
■i-i"
row of plate. lOOpl of 2% horse blood was added into each well. The plate was
I
covered by a lid and incubated at 37°C for 30 minutes. The R-plate was centrifuged at 
lOOOrpm for 1 minute and lOOpl of supernatant from each well was transferred into a 
fresh F-plate by multi-channel pipette. The absorbance was measured by the
I
I
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erythrocytes were also prepared with sterile water. 1ml of horse blood was
centrifuged for 1 min at 13k rpm in an eppendorf tube. The supernatant was removed 
and the pellet was resuspended in same volume of water. The cell suspension was 
centrifuged and the supernatant was removed again. The same process was repeated 3 
times. 10 pi of horse blood and Ipl of proteins were added into 500 pi eppendorf 
tubes, and incubated at ?>TC for 15 minutes. 1 pi of each sample was put on 
microscope slide and covered with a cover glass after the samples were washed 3 
times using PBS in order to clean the excess proteins. The specimens were observed
I
i
under microscope with ulfraviolet (UV) light.
iI
:
s
i
2.3,5. Cell binding assay by fluorescence-activated cell sorter (FACS)
Flow cytometry was performed using FACS. 4% horse blood was prepared by adding
800pi washed FIBC into 20ml PBS. All proteins were diluted to 14nM/L, 140nM/L 
and 1400nM/L concenhation. 500 pi of 4% horse blood and 500pl of protein sample 
were added into the eppendorf tubes. The mixture was transferred into FACS tubes 
and read by FACS after they were incubated at 2>TC for 15 minutes.
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2.3,6. Lipopolysacchride (LPS) levels in purifled recombinant 
proteins
E. coli is a Gram-negative bacteria, LPS is the naturally of component of cell wall of 
Gram-negative baeteria. LPS is highly immunogenic, high level of LPS will 
apparently interfere mouse immunisation study. An in viho kinetic, colorimetric, 
quantitative chromogenic, limulus araebocyte lysate (LAL) assay (Kinetic-QCL®) 
(Cambrex, Nottingham, UK) was used to determine the level of contaminating Gram- 
negative LPS in all protein samples. The assay was lun following manufacturers 
instructions and with help of Dr. Gill R. Douce.
2.4 Structure study of PLY
D4ePLY and D123PLY purified from terrific broth were concentrated to 10 mg/ml in 
sterile PBS by amicon ultra centrifugal filters (Millipore); the concentration was 
determined by measuring OD value by spectrophotometer. 0.5 ml of 1 Omg/ml 
D4ePLY and D123PLY were mixed with different solvents in order to obtain crystal, 
which is used for X-ray crystallography analysis. Dr Allen Ribaldi Tunnicliffe helped 
with all experiments with X-ray crystallography. 0.5 ml of 1 Omg/ml D4ePLY was
analysed by the high field Nuclear Magnetic Resonance (NMR) spectroscopy. N^^ 
labelled D4ePLY and PLY purified from M9 minimal medium were concentrated to 5 
mg/ml and 3mg/ml separately, and then were analysed by NMR spectroscopy. Water- 
soluble and insoluble cholesterol (Sigma) was used to map the binding site of PLY.
Dr Brian Smith fi'om University of Glasgow generated all data with NMR.
2.5. Mice immunisation study of purified recombinant proteins
In vivo experiment were performed in accordance with the UK Animals 1986 
(Scientific Procedures Act). Food and water ad libitum were provided and mice were 
left at a constant room temperature of 20-22 with a 12 hours light/dark cycle. All 
animal was handling was done by Dr. Gill R. Douce. The sample processing, data 
acquisition and interpretation was carried out by the author, Jiang Tao Ma.
2.5.1. Intranasal challenge of mice
Six to eight week-old female mice (Harlan 01ac,UK) were intianasally immunised 3 
times with purified proteins on days 1, 27 and 54 in the groups shown in table 2.5.1. 
The experiment was based on giving 0.2pg of wild type (WT) PLY toxin and ten 
times equimolar concentration of D123PLY and D4PLY, and the final vaccine dose is 
30jul. Group 1 was immunised with 0.2pg of PLY and 0.1 pg of eGFP, which ensure 
the ratio of PLY and eGFP was identical to that present in an equivalent dose of the 
eGFPPLY protein in group 2; group 2 was immunised the equimolar concentration of 
eGFPPLY,; group 3 was immunised ten times equimolar concentration of D4PLY and 
eGFP; group 4 was immunised ten times equimolar concentration of eGFPD4PLY 
and eGFP; group 5 was immunised ten times equimolar concenfration of D123PLY 
and eGFP; group 6 was immunised ten times equimolar concentration of
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.eGFPD123PLY and eGFP; gi'oup 7 was immunised ten times equimolar concentration 
of eGFPD4PLY and 0.2pg of PLY; group 8 was immunised ten times equimolar
Table 2.5.1, Mice immunisation stndy of purified recombinant 
proteins
Group Antigens used Number of mice
1 eGFP, PLY 6
2 eGFPPLY 5
3 eGFP, D4ePLY 54 eGFPD4ePLY 5
5 eGFP, D123PLY 5
6 eGFPD123PLY 5
7 eGFPD4ePLY, PLY 5
8 eGFPD123PLY, PLY 5
concentration of eGFPD123PLY and 0.2pg of PLY. Mouse sera from the day before
.vaccination were collected. Anti-eGFP and anti-PLY IgG response within individual 
serum samples were measured by enzyme linked immunoasorbent assay (ELISA).
s
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2.5.2. Measuring anti-eGFP by ELISA
Flat-bottomed 96-well plates (Nunc' '^^) were used for ELISA. Plate wells were coated 
,lOOpl of Ipg/ml eGFP in PBS overnight at 4°C. The plates were washed three times 
in PBS-T (PBS plus 0.05% Tween 20) and dried thoroughly. The plates were blocked
with 200pl/well of 1% BSA in PBS (Sigma-Aldrich) and incubated for 1 hour at 37°C.
A .
The plates were washed 3 times in PBS-T and dried thoroughly. The plates were then 
incubated at 37°C with lOOpl/well of serial dilution of the serum in duplicate (started 
at 1:50) in PBS for 2 hours. The plates were washed 3 times in PBS-T and dried 
thoroughly. The plates were incubated for 1 hour at 37°C with lOOjul/well of a 1:1000
A
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dilution of anti-mouse anti-IgG HRP conjugate (Amersham, UK) in washing buffer.
In the negative control, lOOpl/well of fresh coating buffer was added; in the positive
control, a mouse serum that has been tested active was added. The plates were washed
3 times in PBS-T and dried thoroughly. 50pl /well of developing solution (Appendix I) 
■were added into each well. The plates were incubated for 5 min at 37 C and the 
reaction was stopped with SOpl/well of 3M Hydrochloric acid. The absorbance was 
read by spectrophotometer (96 well plate reader) at 490nm and titres were calculated 
as the reciprocal of the highest serum dilution, which gave an absorbance of 0.3. A
2.5.3. Measuring anti-PLY IgG by ELISA
All the steps are the same as above except that plate wells were coated withlOOpl of 
2.5|_ig/ml WT PLY in coating buffer (Appendix I) overnight at 4°C. A
2.6 Statistical analysis
The GraphPad® Instat (GraphPad® Instat Software Inc., San Diego, CA) were used 
for analysing data. Antibody production experiment fit normal distribution, but only 5 
samples in each group, so unpaired t-test was used to comparing antibody production 
between different groups.
.''3
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3.1. Construction of pET33b-eGFPD4ePLY, pET33b-eGFPD4PLY  
and pET33b-eGFPD123PLY
pET33b-eGFPD4ePLY, pET33b-eGFPD4PLY and pET33b-eGFPD123PLY were 
constructed in this work. pET33b-D4PLY, pET33b-D4ePLY, pET33b-123PLY and 
pET33b-eGFPPLY were constructed by Mr Graeme J.M.Cowan. The results from 
PCR (Figure 3.2.) confirmed the transformation o f plasmids was successful. The size 
of PCR product for pET33b-eGFPD4PLY, pET33b-eGFPD4PLY and pET33b- 
eGFPD123PLY should be 1382 bps, 1397 bps and 2117 bps (Invitrogen Vector NTI 
Advance 10). The result from PCR (Figure 3.2.) suggests eGFPD4ePLY, 
eGFPEMPLY and eGFPD123PLY gene has been constructed.
Figure 3.1. Plasmid map of pET33b-eGFPD123PLY constructs.
The picture is made by Vector NTT™ Advance 10 software (Invitrogen)
Mori T7 term
KanR
pBR322 or!
C-term His Tag 
D123PLY
pET33b-eGFPD123PLY
7147 bp
eGFP
Nhe I (1995) 
PKA site 
N term His Tag 
T7 promoter
B g l l l  (2180)
Lad
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Figure 3.2. Result of PCR
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
2000bp
lOOObp
•  m r n m m m r n
Lane 1. 1Kb plus DNA ladder (Invitrogen); lane 2, control; lanes 3-6, eGFP- 
D123PLY is 2117 bp; lanes 7-11, eGFP-D4ePLY is 1397 bp; lanes 12-16, eGFP- 
D4PLY is 1382 bp.
Both data from the Molecular Biology Support Unit, University o f Glasgow and the 
DBSGENOMICS at Durham University show no mutation in the sequence o f  
eGFPD4PLY, eGFPD4PLY and eGFPD123PLY.
3.2. Protein purification
eGFPPLY, eGFPD123PLY, eGFPD4ePLY, PLY, D123PLY and D4ePLY, in total, 
six recombinant proteins were purified using a two-step method o f Nickel affinity 
chromatography (NAC) and anion exchange chromatography (AEC). eGFPD4PLY 
was poorly expressed, on contrast, eGFPD4ePLY was expressed much better than 
cGFPD4PLY and no further experiment was done with eGFPD4PLY, which indicate 
the extension between eGFP and domain 4 o f PLY can increase the solubility of 
recombinant protein.
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3.2.1 Purification of eGFPD123PLY
Figure 3.3. Shows a representative NAC purification o f eGFPD123PLY by SDS- 
PAGE. The different lane number represent different fractions, 8pi o f samples were 
loaded in each lane. 20 fractions were collected during NAC purification o f  
cGFPD123PLY. Marker is broad range marker (New England Bio labs), negative 
control is loading buffer, and positive control is previous purified recombinant 
eGFPPLY, whose molecular weight is 83 kDa. Fractions 3-8 contain a large amount 
o f recombinant eGFPD123PLY, whose molecular weight is 70kDa, but contain a 
large amount of the other proteins, and were discarded. Fraction 9-15 were kept and 
used for next step AEC purification (Figure 3.2.1.2).
Figure 3.3. SDS-PAGE gel of eGFPD123PLY after NAC purification.
Marker -vc+vc 1 2 3 4 5 6 7 Marker 8 9 10 II  12 13 14 15
62  —
During AEC purification, eGFPD123PLY bound to the negatively charged column, 
and were washed completely, then was eluted with O.IM NaCl. The column was 
finally cleaned with 3M NaCl. There are two peaks in the picture, the protein level is 
much higher than DNA in the first peak, the protein level is much lower than DNA 
level in the second peak, which mean there are much less DNA in the protein sample
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and DNA has been efficiently moved by AEC because the first peak represents the 
fraction was collected and the second peak represent the waste.
Figure 3.4. AEC purification of eGFPD123PLY
II:n
: J :
0 . 5 0 . 5
2 
5 4: i0 . 0  f- -A' 0.0
Anion exchange Chromatography o f eGFPD123PLY. The green line is A280nm 
protein reading, which measures protein content. The blue line is A254nm DNA 
reading, which measures DNA content. The pink line represents NaCl concentration 
(M); the yellow line represents the pressure in the column.
The eGFPD123PLY peak from Figure 3.4. was dialysed three times at 4°C, 7 hours 
each time with 3L pre-chilled PBS buffer. 2ml o f purified eGFPD123PLY was added 
into amicon centrifugation filters and were concentrated to almost 0.5ml. 0.5ml sterile 
PBS was added into filters and centrifuged again, this process was repeated 5 times.
In Figure 3.5, SDS-PAGE gel shows the contaminant level o f eGFPD123PLY was 
reduced significantly conearing to Figure 3.2.1.1. after using Amicon centrifuge tube.
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Figure 3.5. SDS-PAGE gel of eGFPD123PLY dialysis 
Markei -ve 1 2 3 4 5
83kDa—
62 -►
1 pl o f eGFPPLY protein was loaded in Lane 1, 8pi o f eGFPPLY was loaded in Lane 
2, Ipl o f eGFPD123PLY protein was loaded in Lane 3, 3pi was loaded in Lane 4, and 
8pl was loaded in Lane 5.
Figure 3.6 SDS-PAGE gel o f eGFPD4ePLY after NAC purification
Marker -\ e 8 9 10 11 12 13 14
83kDa-^
62 -►
47.5
325
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Figure 3.6. shows a representative NAC purification o f eGFPD4ePLY by SDS-PAGE. 
The different lane number represent different fractions, 8 pi o f samples were loaded in 
each lane; MW of recombinant eGFPD4ePLY is 44kDa. 20 fractions were collected 
during NAC purification o f eGFPD4ePLY. Fraction 9-16 were kept for further 
purification. The eGFPD4ePLY was further purified as eGFPD123PLY.
Figure 3.7. SDS-PAGE gel o f eGFPPLY after AEC purification
Maikei' e 1 2
62
In Figure 3.7. the samples were loaded in 10% SDS-PAGE gel, Ipl o f protein was 
loaded in Lane 1, and 8pl was loaded in Lane 2. The gel was stained with coomassie 
brilliant blue solution. Negative control is loading buffer, MW of recombinant 
eGFPPLY is 83kDa. eGFPPLY was purified as the same as eGFPD123PLY.
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Figure 3.8 SDS-PAGE gel of PLY after NAC purification
Marker-ve-fve 5 6 7 8 9 10 11 12 13 14 15 16 17 18 +ve Marker
73kDa-^ ' ' AT T'T 83kDa
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Figure 3.8. Shows a representative NAC purification o f PL Y by SDS-PAGE. The 
different lane number represent different fractionsSpl of samples was loaded in each 
lane; MW o f recombinant PLY is 57 kDa. 20 fractions were collected during NAC 
purification of PLY. Fractions 10-17 were kept for further purification. The PLY was 
further purified as eGFPD 123PLY.
Figure 3.9. SDS-PAGE gel of D123PLY after AEC purification 
Maifrci -VC 10 11 12 14 16 18 20 22
50kDa
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Figure 3.9. Shows a representative NAC purification o f 123PLY by SDS-PAGE. The 
different lane number represent different fractions, 8pi o f samples were loaded in 
each lane; MW of recombinant D123PLY is 44 kDa. 25 fractions were collected
44
during NAC purification o f 123PLY. Fractions 16-22 were kept for further 
purification. The D123PLY was further purified as eGFPD 123PLY
Figure 3.10. SDS-PAGE gel of D4PLY after AEC purification 
M aikcr -ve 9 10 13 16 19 21 22 24
5(M )a
20kDa
15kDa
Figure 3.10. Shows a representative NAC purification of D4ePLY by SDS-PAGE. 
The different lane number represent different fractions, 8pl o f samples were loaded in 
each lane; MW of recombinant D4ePLY is 18 kDa. 25 fractions were collected during 
NAC purification o f D4ePLY. Fractions 16-25 were kept for fiirtlKjr purification. The 
D4ePLY was further purified as eGFPD 123PLY.
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4.1. SDS-PAGE and W estern Blotting
The purity o f purified reeombinant proteins were further analyzed by SDS-PAGE and 
Western Blotting. Figure 3.1. show highly pure recombinant proteins were produced. 
Figure 4.2. shows these purified protein are PLY or PLY derivatives and there are 
slight degradation in eOFP tagged proteins.
Figure 4.1. SDS-PAGE (a) and W estern Blotting (b) analysis of the 
purified recombinant proteins.
A
100
Markn 1— 1 2 3 4 5100’5 __B
50
r
20
15
50
25
20
15
10
1 pg o f each sample was loaded on gel and the gel was stained with coomasie brilliant 
blue solution. Anti-Ply antibody was used for Western Blotting. Lanel, negative 
control; lane 2, eOFP-PLY is 83 kOa; lane 3, eCFP-D123PLY is 70 kDa; lane 4, 
eOFP-D4PLY is 42 kDa; lane 5, PLY is 57 kDa; lane 6, D123PLY is 44 kDa; lane 7, 
D4PLY is ISkDa.
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Figure 4.2. Overloaded SDS-PAGE analysis of the purified
recombinant proteins
Marker 1 2  3 4 5 < i " 8250 kDa 
100
50 # 0
37 ■ ■' ■
25
20
15
In Figure 4.2., lanel, negative control; lane 2, PLY is 57 kDa; lane 3 & 4, D123PLY 
is 44 kDa; lane 5, D4ePLY is 18 kDa; lane 6, eGFPPLY is 83 kDa; lane 7, 
eGFPD123PLY is 70 kDa; lane 8, eGFPD4PLY is 42kDa.
4.2. Concentration of purified recombinant proteins
Protein concentration was measured using a standard Bradford assay (Figure 3). The 
concentration o f eGFPPLY was 513 pg/ml, eGFP-D123PLY was 450 pg/ml, eGFP- 
D4ePLY was 434pg/ml, PLY was 347 pg/ml, D123PLY was 536pg/ml and D4PLY 
was 441pg/ml (Table 4.1.). eGFPPLY was expressed at 37®C, when expression 
temperature was changed to at 30*^ C, the production o f eGFPPLY increases 20 fold. 
The other proteins except eGFPPLY and PLYcannot be expressed at 37®C.
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Table 4.1.  Concentration and yield of the purified recombinant 
proteins
Protein sample Concentration ((pg/ml) Yield (mg/L)
eGFPPLY 513 80
eGFPD123PLY 450 100
eGFPD4ePLY 434 50
PLY 347 50
D123PLY 536 25
D4ePLY 441 20
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4.3. Haemolytic assay
The purified proteins were analysed in a haemolytic assay to determine their specific 
activity. The purified recombinant PLY and eGFPPLY retains very strong haemolytic 
activity (Figure 4.3.C). InM of recombinant PLY and eGFPPLY was able to 
completely lyse 2% horse blood. The haemolytic activity of PLY and eGFPPLY are 
3.9x10"  ^HU/mg and 2.75 xlO^ HU/mg respectively. The same molar concentration of 
PLY and eGFPPLY has the same haemolytic activity, which indicates eGFP fusion 
does not interfere haemolytic activity of PLY. Truncated fonns of PLY have no 
haemolytic activity at all even at 3000nM. Interestingly, the high concentration of 
D4ePLY and eGFPD4ePLY caused horse erythrocytes to form aggregate in PBS
■3
solution (Figure 4.3.A and B); the high concentration of D123PLY and
eGFPD123PLY were able to clean the horse erythrocytes in the PBS, the supernatant
.in the high concentration of D123PLY and eGFPD123PLY is clearer than that its 
control (PBS) (Figure 4.3.A and B).
...'Yi
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4.4. Cell binding assessed by Fluorescence M icroscopy
erythrocytes but cGFPD4ePLY did not. These results are consistent to the findings in 
the haemolytic assay. Furthemiore, eGFPD4ePLY bound horse erythrocytes to form a 
large aggregate, which is also consistent to the findings in the haemolytic assay.
4.5. Cell binding assessed by FACS
In Figure 4.5., flow cytometiy analysis further confirmed the finding with florescence 
microscope, eGFPD4PLY binds to horse eiythrocytes, and eGFPD123PLY does not 
bind to horse erythrocytes. More fluorescent cells were detected with increasing of 
concenti’ation of eGFPD4PLY, but not with eGFP and eGFPD123PLY; the horse 
erythrocytes were lysed at 7nM eGFPPLY since InM eGFPPLY is enough to lyse 2% 
horse erythrocyte.
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Florescence microscopy images (Figure 4.4.) showed eGFPPLY and eGFPD4PLY 
but not eGFPD123PLY bind to horse eiythrocytes, and eGFPPLY lysed horse
I
I
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.Figure 4.3. Haemolytic activity of purified recombinant proteins.
A
PBS
etJFPPT.Y
étîFPD i:3F1A
eilFPD-lePLY
B
PBS
PLY
DI23PLY
L)4ePLV
Serial dilution
C  | l O n  
8  95-^ as-tSI :■C 35- 
25- 
15- 
5-
-5
O
«2
>» » * * # *
■ PLY 
A eGFPPLY 
-^eGFPD123PLY 
O-0GFPD4PLY 
- é -  D123PLY 
^ D 4 P L Y
I I I I ■ I I0.01 0.1 1 10 100 1000 10000
Protein conc. (nMfL)
In A and B, the concentration o f proteins are decrease from the left to the right.
51
Figure 4.4. Fluorescence microscopy images
X 100
(A)&(C eGFPPLY binds to horse erythrocytes; (B) eGFPD4PLY binds to horse 
erythrocytes without lysis; (D) eGFPD123PLY does not bind to horse erythrocytes.
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Figure 4.5. Flow cytometry analysis
Flow cytometry data was plotted using WinMDI (http://facs.scripps.edu)
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4.6. Quantification of LPS contamination in purified recombinant 
proteins
Table 3,2. LPS Levels in purified recombinant proteins
Protein samples LPS Concentration (lU/pg)
eGFPPLY 0.35-0.37
eGFPD123PLY 0.334-0.373
eGFPD4ePLY 0.067
PLY 0.103
D123PLY 0.047
D4ePLY 0.065-0.068
eGFP 1.88
no ciystal was fonned.
54
Purified recombinant eGFPD4ePLY, PLY, D123PLY and D4ePLY have very low 
LPS level, which less than or equal to 0.1. LPS level in eGFPPLY, cGFPD123PLY 
and eGFP are much higher than the others, but still acceptable for immunization 
studies.
4.7 Structural characterisation of PLY
In protein precipitation experiment for X-ray crystallography, D123PLY precipitated 
heavily and quickly, and no crystal could form, which mean the concentration of
D123PLY is too high. About 50% of samples with D4ePLY started to precipitate, but
5
S
In the parallel to X-ray crystallography, NMR spectroscopy was used to solve the
structure of PLY. Figure 4.7.1. shows D4ePLY was well folded since the protein
signals were well visible, well dispersed and sharp. Chemical shift (frequency) gives
.you information about which line comes from which chemical group, but proteins are
■I
I
adding water soluble cholesterol, which could imply interaction between water 
soluble cholesterol and individual amino acid. A tryptophan is the most perturbed 
residue (see the arrow). However, the experiments need to be repeated and controlled 
for pH.
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made up of many thousands of atoms, which have similar chemical environments, so 
spectra are overlapped.  ^ labelled D4ePLY and PLY were purified and analysed by
high field NMR spectroscopy. 2-D heteronuclear single quantum coiTelation
(HSQC) of spectrum of D4ePLY (Figure 4.7.2.) and PLY (Data not show) were 
.generated, which can be used for mapping the binding site of PLY. Recombinant PLY 
and eGFPPLY maintain properties of native PLY, and NMR data show purified 
recombinant proteins are well folded, so immunogenic and structural properties of
PLY can be studied extensively with these proteins.
I
Cholesterol in the cell membrane has been considered to be the binding site for PLY.
So next we sought to map the binding site of the interacting amino acids in D4ePLY
to cholesterol by chemical shift perturbation. The difference of HSQC spectrum 
.between samples is called chemical shift peiturbation spectroscopy. Figure 4.7.3.
shows oveiiayed 2-D ^^ N HSQC experiments from the free D4ePLY and the mixture
of D4ePLY with water insoluble cholesterol. Each spot is derived from an amide
nitrogen and its attached proton so there is a spot for each residue in the protein.
Shifts in the position of the spots when the peptide binds indicate changes in
environment. There is no significant shifts on adding cholesterol, which implies no 
. . .binding, but it could be solubility problem of cholesterol we used. Figure 4.7.4. shows
...|
oveiiayed 2-D *^ N HSQC experiments from the free D4ePLY and the mixture of 
D4PLY with water-soluble cholesterol. There are small, but significant shifts on
:,V
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Figure 4.7.1. Chemical shift experiments for unlabelled D4ePLY
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Figure 4.7.2. Chemical shift experiments for labelled D4ePLY
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2-D heteronuclear single quantum correlation (HSQC) o f spectrum o f D4ePLY 
recorded at 600MHz (*H) and 298K in PBS on a Bruker AVANCE spectrometer 
equipped with cryoprobe. Each spot is derived from an amide nitrogen and its 
attached proton so there is a spot for each residue in the protein.
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Figure 4.7.3. Chemical shift perturbation experiments for water insoluble
cholesterol binding o f  1 labelled D4ePLY
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Chemical shift (PPM)
2-D '^N HSQC o f spectrum o f D4ePLY recorded at 600MHz and 298K in PBS on a 
Bruker AVANCE spectrometer equipped with cryoprobe. Each spot is derived from 
an amide nitrogen and its attached proton so there is a spot for each residue in the 
protein.
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Figure 4.7.4. Chemical shift perturbation experiments for water-
soluble cholesterol binding of labelled D4ePLY
e>
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Chemical shift (PPM) 1h
2-D HSQC o f spectrum o f D4cPLY recorded at 600MHz and 298K in PBS on a
Bruker AVANCE spectrometer equipped with cryoprobe. Each spot is derived from 
an amide nitrogen and its attached proton so there is a spot for each residue in the 
protein.
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Chapter 5
Results
Mouse immunisation study of 
purified PLY and its derivative
proteins
60
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5.1. Immunising mice with purified proteins
Group 1 to 6 (Harlan Olac, UK) were intranasally immunised 3 times with purified 
proteins on days 1, 27 and 54. Group 7 (table 5.1.) and 8 (table 5.1.) were intranasally 
immunised 2 times on days 1 and 54. Bleeds were taken one day before each 
immunisation; the last bleed was taken two weeks after the third boost (day 54). 
However, group 7 and 8 were bled 4 times the same as the others (day 0, 26, 53 and 
67), but immunised twice (day 1, day 54). One mouse died in-group 2 and three mice 
died in group 7 (Table 5.1.) the day after first immunisation. Anti-eGFP and anti-PL Y 
IgG antibody were measured in all samples of every bleed (Figure 5.1.D and 
Figure5.2.E).
Table 5.1, Groups of mice used for immunisations
Group Antigens used Number of mice
1 eGFP, PLY 6
2 eGFPPLY 4
3 eGFP, D4ePLY 5
4 eGFPD4ePLY 5
5 eGFP, D123PLY 5
6 eGFPD123PLY 5
7 eGFPD4ePLY, PLY 2
8 eGFPD123PLY, PLY 5
5.2. Immune response in mice immunised with purified proteins.
No anti-eGFP IgG antibody was detected in the first bleed of all the groups (Figure 
5.1.D), and no anti-eGFP IgG were detected in the group 3 and 5 (Figure 5.1.D). ). 
Mice intranasally challenged with very low level of eGFPPLY (0.2/xg) rapidly 
produced of high levels of IgG antibody to eGFP, but intranasal administration of 
mixture of eGFP and PLY were unable to induce the above response (Figure 5.1.D).
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There were detectable levels of anti-eGFP IgG antibody in-group immunised with 
eGFPPLY after the first immunisation (day 26), and the level of aiii-eGFP IgG 
increased significantly after each boost (Figure 5. LA and D), but no anti-eGFP IgG 
was detected in group immunised with eGFP and PLY (Figure 5.LD). Interestingly, 
no anti-eGFP IgG antibody was produced in group 4 (eGFPD4ePLY) and 6 
(eGFPD123PLY), but high level of anti-eGFP IgG and detectable level of anti-eGFPP 
IgG were found after one boost in group 7 and 8(Figure 5.1.B-D). The results for 
group 4, 6, 7 and 8 showed intranasal administration of eGFP tagged truncated form 
of PLY are unable to induce anti-eGFP IgG response in mice unless the intact PLY 
was administrated simultaneously (Figure 5.1B-D).
I
Figure 5.1. Anti-eGFP IgG response over time in mice immunised 
with different of antigens
A Mice immunised with eGFPPLY
%II1!
500000
50000
5000
500
50 26 53 67
Sample days
i
:
'7:':
I
62
s
■
B Mice immunised with mixture of eGFPD4ePLY and PLY
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In A, B and C, Each dot represents an individual mouse and each line presents the 
mean response of total mice. D shows mean anti-eGFP IgG titre at OD490nm0.3 
(±SEM) in mice before each challenge. Each bar represents the geometric mean titre 
of total mice and each eiTor bar the standard deviation from the mean. The detection 
limit of anti-PLY IgG titi'e is 50.
Figure 5.2. Anti-PLY IgG response over time in mice immunised with 
different combination of antigens
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. 1;In A, B, C and D, each dot represents an individual mouse and each line presents the
:mean response of total mice. E shows mean anti-PLY IgG titre at OD490nm0.3 
(±SEM) in mice before each challenge. Each bar represents the geometr ic mean titre 
of total mice per group and each enor bar the standard deviation from the mean. The 
detection limit of anti-PLY IgG titre is 50.
No PLY specific IgG was detected in the first bleed of all mice, and no PLY specific 
IgG was detected in the serum of group 3, 4, 5 and 6 (Figure 5.2.E). Low level of anti- | |
PLY IgG was detected in the second bleed of group 1, 2, 7 and 8, but high level anti- 
PLY IgG was detected after boost (Figure 5.2.A-E). These results means intranasal 
administi'ation of PLY but no tiuncated form of PLY is able to elicit immune response 
in mice.
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Chapter 6
Discussion
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Vectors pET33b-eGFPD4PLY, pET33b-eGFPD4PLY and pET33b-eGFPD123PLY 
were successfully constructed. A large amount, highly pure recombinant of eGFPPLY, 
eGFPD123PLY, eGFPD4PLY, PLY, D123PLY and D4PLY with low levels of 
contaminating LPS were obtained using NAG and AEG two step purification. All 
protein can be expressed at 37“C and 30°C, but can not be purified due to formation of 
inclusion body at 37°C except eGFPPLY and PLY, and the yield of eGFPPLY and 
PLY protein at 30°C increased 20 and 5 fold respectively comparing to that at 37“C 
(data not show), which suggests the solubility of protein increases with decrease of 
temperature. The results from fluorescence microscopy and flow cytometry showed 
that D4ePLY is capable of binding to horse erythrocyte membrane, but D123PLY is 
not, and both D4ePLY and D123PLY are not able to lyse horse erythrocytes, which is 
consistent to results from Baba et al. However, Baba and his colleagues (Baba, 
Kawamura et al. 2001) used immunoblotting for detecting cell binding property of 
PLY and D4ePLY, and the maximum concentiation in their haemolytic assay is about 
100iiM,the maximum concentration in our assay is over 3mM.
In our haemolytic assay, the phenomenon that D4ePLY caused horse erythrocytes to 
fomi aggregates in PBS solution has also been found in PLY and PLY mutant 
(unpublished data); fluorescence microscopy images (Figure 4.4.) further showed this 
phenomenon with D4PLY and PLY. The reasons why D4PLY cause horse 
erythrocytes to aggregate still remain unclear, further investigation will be conducted.
An alternative membrane binding site, rather than the D4ePLY cholesterol binding 
site has been suggested. High concentrations of D123PLY were shown to induce y- 
interferon and NO in mouse spleen cells(Baba, Kawamura et al. 2002). The results
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suggested that was independent of cholesterol binding and pore forming ability of 
PLY. The clearance property of D123PLY in haemolytic assay (Figure 4.3.A and B) 
has been found in wild type non-haemolytic PLY (unpublished data). Thought the 
mechanism of causing clearance is not clear, it suggests physical contact showed 
occurred between horse erythrocyte and D123PLY, which means the second cell 
membrane binding site may exist in domain 123 of PLY except the cholesterol 
binding site in domain 4 of PLY. This will be further investigated by rat mast cell 
degranulation assay and cell binding assays.
Mice intranasally challenged with very low level of eGFPPLY (0.2g,g) rapidly 
produced of high levels of IgG antibody to eGFP, but intranasal administration of 
mixture of eGFP and PLY were unable to induce the above response (Figure 5.1.), 
which confirmed the previous finding that PLY can act as a mucosal adjuvant to 
eGFP when eGFP and PLY are genetically linked but not unlinked. Intranasal 
administration of eGFP tagged truncated form of PLY are unable to induce anti-eGFP 
IgG response in mice unless the intact PLY was administrated simultaneously (Figure 
5.1 .B-D). These results mean that free PLY could act on an adjuvant when eGFP
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Results of Chemical shift experiments for both labelled and unlabelled 
D4ePLYfurther show D4ePLY is well folded, and Chemical shift experiment for 
labelled PLY show PLY is well folded. A tryptophan was suggested to be involved 
interaction of PLY with water-soluble cholesterol (Figure 4.7.4.) However, 
and 1 double labelled PLY and D4ePLY needs to be purified in order to obtain 
NMR structure of PLY for further mapping mechanism of binding of PLY to
■cholesterol.
linked to truncated fomi of PLY, and part of PLY maintain adjuvant properties of 
PLY. High level of anti-PLY IgG was detected in the groups immunised with PLY 
and eGFPPLY, but not found in groups immunised with truncated form of PLY 
(Figure 5.2.), which means PLY remain highly immunogenic after genetically linked 
to another protein.
The pervious work in our graup also suggests AA146PLY, a mutant which has lost 
haemolytic property totally but as immunogenic as native PLY without its associated 
effects (Kirkham, L. A. et al. 2006), can still act as a adjuvant in eGFPAA146PLY 
fusion during immunisation study. Since the adjuvant property of native PLY is better 
PLY mutant, so the adjuvant property: PLY> AA146PLY > huncated 
PLY( D 123PLY and D4ePLY). Because the PLY mutant retains the adjuvant property
For the next step, the eGFP protein needs to be replaced with a pneumococcal protein. 
One or more fusion proteins are expected to elicit serotype independent protection, 
which would provide a broader protection against S. pneumoniae. The adjuvant
vaccine. PsaA may be a good candidate to form a fusion protein with PLY. PsaA has
'Vof native PLY, it would be interesting to see if anti-eGFP antibody can be produced in 
. .mice immunised with mixture of AA146PLY eGFP tagged truncated PLY.
I
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property of PLY may exist in the other member of cholesterol dependent cytolysin 
family. In addition,' the fusion protein can also be used in polysaccharide conjugate
shown significant protection against colonization but less protective in against 
invasive disease (Briles et al., 2000 and 1997; Seo et ah, 2002). Fusing PsaA to PLY 
would be expected to eliminate nasopharyngeal colonization of pneumococcus and
70
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provide a broad protection against the pnenumococcal diseases. The eGFP protein can 
also be replaced with proteins from the other pathogen for developing new vaccines.
A potential problem with mucosal vaccine is that cross-reactivity of mucosal vaccine 
can reduce, even eradicate of some species of nature microflora on the surface of gut 
and respiratory tract, these species can protect humans from diseases infected by the 
pathogens other than pneumococcus.
The availability of highly purified recombinant eGFPPLY, eGFPAA146PLY, 
eGFPD4PLY and eGFPD123PLY in our group will accelerate investigation into the 
mechanism of pore foiming with PLY, and toxin cell tmfficking can also be studied. 
The truncated fomi of PLY will be used in stmcture studies of PLY.
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Appendix I
Buffers and Recipes
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Appendix I (buffers and recipes)
A, Media recipes
LB broth
1 Og Tryptone
lOgNaCl
5 g Yeast Extract
In IL of dH20, autoclave.
LB Agar
1 Litre of LB Broth as above plus lOg Bacteriological Agar 
Autoclave, store at RT.
Melt in microwave, cool immediately or keep at 60-65°C in water bath, pour plate
Terrific broth (TB)
12g bacto-tiyptone 
24g bacto-yeast extract 
4ml glycerol
Make up to 0.9L with dH%0 and autoclave
In a separate flask dissolve in 100ml dHzO:
2.31 g KH2PO4 monobasic 
12.54g K2HPO4 dibasic (for trihydrate 16.45 g)
M9 minimal medium
5 X M9 stock solution 
64 Na2HP04.7H20 
I5KH2PO4 
2.5g NaCl
Make up to 1L with dH20 and autoclave
1L M9 minimal medium 
200ml 5 X M9 (autoclaved)
2ml 50mM CaCb (filter-sterilised)
2ml IM MgS04 (filter-sterilised)
0.8ml 50mg/ml Thiamine(filter-sterilised)
800ml sterile dH20 (autolaved)
B. Nickel affinity chromatography (NAC) buffer
10 X PBS
80g NaCl 
2gKCl
14.4 Na2l-IP04
2.4 KH2PO4 
In 1 liti-e dH20
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250mM EDTA PH 7.5-8
93.6g EDTA in 1 litre dHzO
250mM imidazole
17.02g imidazole in IL PBS
lOOmM NiS0 4
26.28gN iS04 in ILdHzO
3M guanidine HCl
286.59g guanidine HCl in IL dHzO
C. BioCAD buffer
1 X PBS 
8g NaCl 
0.2g KCl
1.44 Na2HP04 
0.24 KH2PO4
In 1 litre dPLO and autoclave 
3M NaCl
175.32g NaCl in lLdH 20
20% Ethanol
200ml Ethanol A. R.
Make up to IE with dLLO
D. SDS PAGE gel
RUNNING GEL(two gels) 5% 12% 10% 7.5%
dPLO 2.35ml 3.35 4.05 4.85
1.5M Tris pH8.8 2.5ml 2.5 2.5 2.5
10% SDS 0.1ml 0.1 0.1 0.1
30% polyacrylamide 5.0ml 4.0 3.3 2.5
10% ammonium persulphate 0.05ml 0.05 0.05 0.05
TEMED 0.005ml 0.0051 0.005 0.005
STACKING GEL (two gels)
dH20 3.21ml
0.5MTrispH6.8 1.25ml
10% SDS 0.05ml
30% polyacrylamide 0.488ml
10% ammonium persulphate 0.025ml 
TEMED 0.005ml
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5 X sample buffer 
0.6ml 0.5M Tris pH6.8 
5.0ml 50% glycerol 
2.0ml 10% SDS 
1.0ml 1% bromophenol blue 
0.9ml dlhO
!
E.Westerii Blotting
Developer (make just before use)
Dissolve 30mg 4-cliloro-l-napthol in 10ml Methanol 
Add to 40ml Tris NaCl pH7.4 
Add 30pl H2O2 (30% w/v)
E.ELISA
Developing solution (make just before use)
O.IM citric acid 12.25ml
0.25M Na2HP04 12.75ml
■:s
10 X Running Buffer 
30gTris
144g Glycine 
lOg SDS 
Make up to 1L with dH20
I
Transfer Buffer
25mM Tris Base (3.03g) 
192mM Glycine (14.4g) 
20% Methanol (200ml) 
Make up to IL with dH20 
(chilled to 4°C)
Tris NaCl pH7.4
Tris base 1.2g 
NaCl 8.7g
make up to 1L with dH20 
conc. HCl 800pi
■i
I
H2O2 20pi
Fast™ 0-phenylenediamine dihydrochroide tablet one
Unless otherwise stated, all reagents and chemicals are from Sigma-Adlrich, Dorset,
UK
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